Search

Author/Creator O'Sullivan, Joe M

1. A radiobiological model of metastatic burden reduction for molecular radiotherapy: application to patients with bone metastases. (14th March 2017)

Authors:
Denis-Bacelar, Ana M; Chittenden, Sarah J; Murray, Iain; Divoli, Antigoni; Ralph McCready, V; Dearnaley, David P; O'Sullivan, Joe M; Johnson, Bernadette; Flux, Glenn D
Journal:
Physics in medicine & biology
Issue:
Volume 62:Number 7(2017:Apr.)
Page Start:
2859
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Issue 10323 (29th January 2022)

Authors:
Attard, Gerhardt; Murphy, Laura; Clarke, Noel W; Cross, William; Jones, Robert J; Parker, Christopher C; Gillessen, Silke; Cook, Adrian; Brawley, Chris; Amos, Claire L; Atako, Nafisah; Pugh, Cheryl; Buckner, Michelle; Chowdhury, Simon; Malik, Zafar; Russell, J Martin; Gilson, Clare; Rush, Hannah;...
Journal:
Lancet
Issue:
Volume 399:Issue 10323(2022)
Page Start:
447
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Issue 10024 (19th March 2016)

Authors:
James, Nicholas D; Sydes, Matthew R; Clarke, Noel W; Mason, Malcolm D; Dearnaley, David P; Spears, Melissa R; Ritchie, Alastair W S; Parker, Christopher C; Russell, J Martin; Attard, Gerhardt; de Bono, Johann; Cross, William; Jones, Rob J; Thalmann, George; Amos, Claire; Matheson, David; Millman,...
Journal:
Lancet
Issue:
Volume 387:Issue 10024(2016)
Page Start:
1163
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Clinical and functional characterization of CXCR1/CXCR2 biology in the relapse and radiotherapy resistance of primary PTEN-deficient prostate carcinoma. (3rd July 2020)

Authors:
Armstrong, Chris W D; Coulter, Jonathan A; Ong, Chee Wee; Maxwell, Pamela J; Walker, Steven; Butterworth, Karl T; Lyubomska, Oksana; Berlingeri, Silvia; Gallagher, Rebecca; O'Sullivan, Joe M; Jain, Suneil; Mills, Ian G; Prise, Kevin M; Bristow, Robert G; LaBonte, Melissa J; Waugh, David J J
Journal:
NAR cancer
Issue:
Volume 2:Number 3(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Consensus on molecular imaging and theranostics in prostate cancer. Issue 12 (December 2018)

Authors:
Fanti, Stefano; Minozzi, Silvia; Antoch, Gerald; Banks, Ian; Briganti, Alberto; Carrio, Ignasi; Chiti, Arturo; Clarke, Noel; Eiber, Matthias; De Bono, Johann; Fizazi, Karim; Gillessen, Silke; Gledhill, Sam; Haberkorn, Uwe; Herrmann, Ken; Hicks, Rodney J; Lecouvet, Frederic; Montironi, Rodolfo; Os...
Journal:
Lancet oncology
Issue:
Volume 19:Issue 12(2018)
Page Start:
e696
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Issue 8 (August 2016)

Authors:
Dearnaley, David; Syndikus, Isabel; Mossop, Helen; Khoo, Vincent; Birtle, Alison; Bloomfield, David; Graham, John; Kirkbride, Peter; Logue, John; Malik, Zafar; Money-Kyrle, Julian; O'Sullivan, Joe M; Panades, Miguel; Parker, Chris; Patterson, Helen; Scrase, Christopher; Staffurth, John; Stockdale...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 8(2016:Aug.)
Page Start:
1047
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial. Issue 4 (25th July 2022)

Authors:
James, Nicholas D; Ingleby, Fiona C; Clarke, Noel W; Amos, Claire L; Attard, Gerhardt; Brawley, Christopher D; Chowdhury, Simon; Cross, William; Dearnaley, David P; Gilbert, Duncan C; Gillessen, Silke; Jones, Robert J; Langley, Ruth E; Macnair, Archie; Malik, Zafar I; Mason, Malcolm D; Matheson, ...
Journal:
JNCI cancer spectrum
Issue:
Volume 6:Issue 4(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Issue 16 (December 2015)

Authors:
Wilkins, Anna; Mossop, Helen; Syndikus, Isabel; Khoo, Vincent; Bloomfield, David; Parker, Chris; Logue, John; Scrase, Christopher; Patterson, Helen; Birtle, Alison; Staffurth, John; Malik, Zafar; Panades, Miguel; Eswar, Chinnamani; Graham, John; Russell, Martin; Kirkbride, Peter; O'Sullivan, Joe ...
Journal:
Lancet oncology
Issue:
Volume 16:Issue 16(2015)
Page Start:
1605
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Issue 10162 (1st December 2018)

Authors:
Parker, Christopher C; James, Nicholas D; Brawley, Christopher D; Clarke, Noel W; Hoyle, Alex P; Ali, Adnan; Ritchie, Alastair W S; Attard, Gerhardt; Chowdhury, Simon; Cross, William; Dearnaley, David P; Gillessen, Silke; Gilson, Clare; Jones, Robert J; Langley, Ruth E; Malik, Zafar I; Mason, Mal...
Journal:
Lancet
Issue:
Volume 392:Issue 10162(2018)
Page Start:
2353
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗